Quantitative measurement of c-erbB-2 p 185 and mutant p53 expression in ovarian neoplasms by enzyme immunoassay

Clinical Chemistry

Volumn 42, Issue 6 SUPPL., 1996, Pages 981-982

  Mabrouk, Gamal M ^a   Helal, Sahar A A ^a   El Lamie, Khalil I ^a   Khalifa, Ali ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; CYSTADENOMA; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; ONCOGENE C ERB; OVARY CANCER; OVARY TUMOR;

FEMALE; HUMANS; MUTATION; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029975496     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.6.981     Document Type: Article

References (13)

1. Steele GD, Jessup LM, Winchester DP, Murphy GP, Menck HR. Clinical highlights from the national cancer data base: 1995. CA Cancer J Clin 1995;45:102-11.
2. Wong PA, long T, Bolden S. Cancer statistics 1995. CA Cancer J Clin 1995;45:12-3.
3. Mokhtar N, ed. Cancer pathology registry (1989-1989). Cairo, Egypt: National Cancer Institute, Department of Pathology, 1991:1-70.
4. Felip E, Delcampo JM, Rubio D, Vidal MT, Colomer R, Bermejo B. Overexpression of c-erb B-2 in epithelial ovarian cancer. Cancer 1995:75:2147-52.
5. Rubin SC, Rnstad CL, Federici MG, Scheiner L, Lloyd KO, Hoskins WJ. Prevalence and significance of HER-2/neu expression in early epithelial ovarian cancer. Cancer 1994;73:1456-9.
6. Haldane JS, Hird V, Hughes CM, Gullick WJ. c-erb B-2 oncogene expression in ovarian cancer. J Pathol 1990;162:231-7.
7. Singleton TP, Perrone T, Oakley G, Niehans GA, Carson L, Cha SS, Strickler JG. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Cancer 1994;73:1460-6.
8. Rubin SC, Finstad CL, Wong GY, Almadrones L, Plante M, Lloyd KO. Prognostic significance of HER-2/neu expression in advanced epithelial cancer: a multivariate analysis. Am J Obstet Gynecol 1993;168:162-9.
9. Hassapoglidou S, Diamandis EP, Sutherland DJA. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with timeresolved immunofluorometry. Oncogene 1993;8:1501-9.
10. Levesque MA, Katsaros D, Yu H, Zola P, Sismondi P, Giardina G, Diamandis EP. Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 1995;75:1327-38.
11. Nugent A, MacDermott E, Duffy K, O'Higgins N, Fennelly JJ, Duffy MJ. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer. Clin Chem 1992;38:1471-4.
12. Diamandis EP, Levesque MA. Assessment of p53 overexpression by nonimmunohistochemical methods. J Pathol 1995;175:93-5.
13. Bradford NM. A rapid and sensitive method forthe quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.